anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Hypoxia is a critical factor contributing to a poor prognosis and challenging glioma therapy. Previous studies have indicated that hypoxia drives M2 polarization of macrophages and promotes cancer progression in various solid tumors. However, the more complex and diverse mechanisms underlying this process remain to be elucidated. Here, we aimed to examine the functions of hypoxia in gliomas and preliminarily investigate the underlying mechanisms of M2 macrophage polarization caused by hypoxia. We found that hypoxia significantly enhances the malignant phenotypes of U87 and U251 cells by regulating glycolysis. In addition, hypoxia mediated accumulation of the glycolysis product [lactic acid (LA)], which is subsequently absorbed by macrophages to induce its M2 polarization, and this process is reverted by both the glycolysis inhibitor and silenced monocarboxylate transporter (MCT-1) in macrophages, indicating that M2 macrophage polarization is associated with the promotion of glycolysis by hypoxia. Interestingly, we also found that hypoxia mediated LA accumulation in glioma cells upon uptake by macrophages upregulates H3K18La expression and promotes tumor necrosis factor superfamily member 9 (TNFSF9) expression in a histone-lactylation-dependent manner based on the results of chromatin immunoprecipitation sequencing (ChIP seq) enrichment analysis. Subsequent in vitro and in vivo experiments further indicated that TNFSF9 facilitated glioma progression. Mechanistically, hypoxia-mediated LA accumulation in glioma cells is taken up by macrophages and then induces its M2 macrophage polarization by regulating TNFSF9 expression via MCT-1/H3K18La signaling, thus facilitating the malignant progression of gliomas.NEW & NOTEWORTHY Our study revealed that hypoxia induces the production of LA accumulation through glycolysis in glioma cells, which is subsequently absorbed by macrophages and leads to its M2 polarization via the MCT-1/H3K18La/TNFSF9 axis, ultimately significantly promoting the malignant progression of glioma cells. These findings are novel and noteworthy as they provide insights into the connection between energy metabolism and epigenetics in gliomas.
NT3 is a member of the DBNF gp. It is based in part on the identification of regions of nucleic acid sequence homology shared by BDNF and NGF. The regions of homology may be used to identify new members of the BDNF/NGF gene gp. See US application No. 400,591 filed 30 August, 1989. The purified NT-3 protein and its prodn. by growing a host cell comprising the DNA molecule are claimed. The protein may be glycosylated or unglycosylated. Antibodies to NT-3 are also claimed and are produced by immunising a host animal with a neurotrophin-3 protein or its fragment.
Q fever is a zoonosis with a worldwide distribution that is caused by the intracellular bacterium Coxiella burnetii. Although most infections in children are asymptomatic and self-limiting, some experience severe or chronic manifestations. Its manifestations in patients with sickle cell disease are unknown, as there are no reports currently. We report the case of a 4-year-old child with sickle cell disease who was admitted to the intensive care unit with fever, septic shock and fulminant hepatic failure secondary to hepatic sequestration crisis and intrahepatic cholestasis. Coxiella burnetii infection was confirmed by molecular and serologic assays. Empiric therapy with doxycycline had a significant impact on his course, and he made an excellent recovery despite requiring extensive life-supportive measures initially. This is the first report of Q fever in a patient with sickle cell disease, demonstrating its capability to manifest as acute sickle hepatopathy with critical illness.
INTRODUCTION: Severe exacerbations of chronic obstructive pulmonary disease (COPD) are known to increase the risk of cardiovascular events. However, this association has not been investigated specifically in patients with COPD in Japan, whose characteristics may differ from those of Western patients (i.e., western Europe, the US, and Canada).
METHODS: This longitudinal retrospective cohort study analyzed secondary claims data and included patients aged ≥ 40 years with COPD (International Classification of Diseases-10 codes J41-J44). All exacerbations occurring during follow-up were measured. Time-dependent Cox models were used to estimate hazard ratios (HRs) for the association between time periods following an exacerbation of COPD (vs. time prior to a first exacerbation) and occurrence of a first hospitalization for a severe fatal or non-fatal cardiovascular event.
RESULTS: The analysis included 152,712 patients with COPD with a mean age of 73.8 years and 37.6% of whom were female. During a median follow-up of 37 months, 63,182 (41.4%) patients experienced ≥ 1 exacerbation and 13,314 (8.7%) patients experienced ≥ 1 severe cardiovascular event. Following an exacerbation of COPD, the risk of a severe cardiovascular event was increased in the first 30 days [adjusted HR (aHR) 1.44, 95% confidence interval (CI) 1.33-1.55] and remained elevated for 365 days post-exacerbation (aHR 1.13, 95% CI 1.04-1.23). Specifically, the risks of acute coronary syndrome or arrhythmias remained significantly increased for up to 180 days, and the risk of decompensated heart failure for 1 year.
CONCLUSION: Among Japanese patients with COPD, the risk of experiencing a severe cardiovascular event increased following a COPD exacerbation and remained elevated for 365 days, emphasizing the need to prevent exacerbations.
Progesterone (P4) is a steroidal hormone that is required for successful embryo implantation and maintenance of the pregnancy in natural cycles, fresh in vitro fertilization cycles, and frozen embryo transfer (FET) cycles. Women undergoing FET in programmed cycle are unable to provide adequate endogenous P4 and require progesterone supplementation to initiate and maintain the secretory endometrium and pregnancy. There has been previous research into luteal phase support in frozen cycles, which has demonstrated that supplementation of progesterone does impact outcome in FET. Despite this evidence for the role of progesterone, there is surprisingly little data on the optimal values for serum P4 during the luteal phase and specifically on the day of embryo transfer in frozen cycles. Following years of a prevalent belief that the higher values of P4 are better, it seems that there may be an optimal window for P4 values during the luteal phase in bovine IVF. Though progesterone levels on the day of transfer have not yet been studied extensively in humans, tailoring the time of transferring a frozen embryo based on serial P4 values rather than cycle day number alone results in higher pregnancy rates. By direct action on the endometrium, a rise of LH might interfere with endometrial receptivity during a FET cycle, in which no pituitary suppression is used. The significance of LH level on the day before addition of progesterone is not yet well defined. The aim of this study is to investigate the effect of monitoring and follow-up of serum progesterone, estradiol \& luteinizing hormone levels on day of embryo transfer on pregnancy outcomes for FET in programmed HRT cycles in comparison with ultrasound only in control group and to evaluate the effect of progesterone supplements adjustments depending on serum progesterone levels on day of FET in affecting clinical pregnancy rate.
HIV testing will only be done if ordered by the primary care clinician. Individuals diagnosed with HIV who have not yet notified partners will be offered assisted partner notification at a 6-week visit.
For training for and performance of LGE analysis, multi-task machine-learning model is trained to output various cardiac tissue characteristics based on input of LGE MR data. The use of segmentation may be avoided or limited, resulting in a greater number of available training data samples, by using radiology clinical reports with LGE information as a source for samples. The multi-task model may be trained to output cardiac tissue characteristics using radiology clinical reports with LGE information with no segmentation or with segmentation for only a subset of the training samples. By training for multiple tasks, the accuracy of prediction for each task benefits from the information for other tasks. The trained model outputs values of characteristics for multiple tasks, such as extent of enhancement, type of enhancement, and localization of enhancement. Other tasks may be included, such as disease classification. Other inputs may be used, such as also including sensor data and/or cardiac motion.
The invention is based on taking advantage of two effects of Q10 - the antioxidative one, i.e. the preventive one and the "energizing" one, i.e. the revitalizating and regenerating one. By adding Q10 to cosmetic pharmaceutical preparations, the increase in protection power against UV rays is achieved, as Q10 prevents the formation of free radicals or neutralizes them and at the same time, strengthens body cells to become more resistant to damages from UV rays and regenerate more quickly after   eventual damages. Besides, by adding Q10 to preparations for hair, scalp, lips, etc., such as ointments and creams for lips, shampoos, gels, and hair regenerators, which by themselves are not intended for the protection against sunrays, the application value of such products is increased also with regard to the purpose of protection and regeneration after the impact of UV rays, and also improved in general their preventive and regenerative acting against other harmful effects. Q10 is applicable for                                               alleviation or treatment of scalp problems such as dandruff, loss and greasing of hear and baldness. The use of Q10 is characterized in that it is applied as an additive to preparations for protection of exposed body parts against negative effects, preferentially negative effects of the sun or UV rays, wind, cold, heat and chemical substances. The preparations for protection of exposed body parts are characteristic in that they contain Q10 alone or together with other products applied for protection                                              against negative effects.
Dose-dense and dose-intense ABVD regimen (ABVD DD-DI: intercycle 21 days, d1, d11; doxorubicin 35 mg/m2 DD 1 and 11) is given in cycles 1 to 4 and dose-dense ABVD (ABVD DD: intercycle 21 days, D1 and D11; conventional doxorubicin dose, e.g. 25 mg/m2 DD 1 and 11) is given as cycles 5 and 6). The treatment is not PET-adapted, and only patients with no response or progressive disease at interim FDG-PET as defined by the Lugano Classification (e.g., score 4 or 5 on 5PS with no significant change or with increased uptake matched with baseline and/or new FDG-avid foci consistent with lymphoma) will be diverted to salvage therapy. ISRT 30 Gy will be delivered to responder patients (DS=3), on focal PET-positive rests with a residual size ≥ 2.5 cm and on patients in PR with uptake scoring 4 or 5, whichever is the size.
This group of mother-child dyads will have mothers who have been screened for and met diagnostic criteria for depression. Mothers in this group will participate in the 20-week group therapy and parent skills training intervention.
TAK-020 25 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose will be determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 3 in Part 2.
Recent studies suggest an increased risk of reinfection with the SARS-CoV-2 Omicron variant compared with previous variants, potentially due to an increased ability to escape immunity specific to older variants, high antigenic divergence of Omicron from earlier virus variants as well as its altered cell entry pathway. The present study sought to investigate epidemiological evidence for differential SARS-CoV-2 reinfection intervals and incidence rates for the Delta versus Omicron variants within Wales. Reinfections in Wales up to February 2022 were defined using genotyping and whole genome sequencing. The median inter-infection intervals for Delta and Omicron were 226 and 192 days, respectively. An incidence rate ratio of 2.17 for reinfection with Omicron compared to Delta was estimated using a conditional Poisson model, which accounted for several factors including sample collection date, age group, area of residence, vaccination and travel status. These findings are consistent with an increased risk of reinfection with the Omicron variant, and highlight the value of monitoring emerging variants that have the potential for causing further waves of cases.
522,727. Disinfectants and pesticides; medicines. DICKESON, T. W. Sept. 20, 1938, No. 18291. [Class 81 (i)] [Also in Group III] Water repellent disinfectant pesticidal and medicinal solid substances are rendered wettable by admixture with an insoluble gelatinous metallic hydroxide or oxide. The admixture may be made by intimately mixing the hydroxide and solid substance in the presence of much water and then progressively dehydrating to the required consistence which may extend from a thin solution to a powder. An alternative method is to mix the hydroxide and solid substance together with only sufficient water to form a paste and then to grind the mixture, diluting or dehydrating afterwards to the required concentration. The proportion of hydroxide is from 20-100 per cent. of the solid to be used. Examples of suitable hydroxide ores or oxides are those of aluminium, magnesium, copper, lead and zinc, the last three being prepared by precipitation from copper sulphate, lead acetate and zinc sulphate by caustic soda, ammonia and ammonia respectively. Examples of water repellent solid substances are sulphur, carbon black, derris powder, pyrethrum, thiodiphenylamine, lycopodium, guaiacium carbonate, dry vegetable fibres, synthetic dyes and mustard. Protective colloids such as glue or albumen may be added. These dispersions may be added to emulsions and used as insecticides, disinfectants, preservatives, sheep-dips, blow-fly pest sprays, fumigators, or medicinal preparations for internal or external use. Examples of these products are given which mav contain paraffin oil, cotton seed oil, turpentine, kerosene, carbon tetrachloride, naphthalene, nicotine oleate, cresols and organic thiocyanates such as that sold under the Registered Trade Mark " Lethane 384 " in addition to the metallic oxide or hydroxide and water repellent solid substance according to their uses. Specifications 193,520, [Class 1 (i)], 487.855 and 519,619 are referred to.
Prepns. contain (A) dihydroergotamine or a salt thereof with an acid, (B) heptaminol or a salt thereof with an acid, and (C) usual carriers and/or diluents and/or adjuvants; the molar ratio of component (A) to component (B) being 1:40 to 1:2000. Prepns. are used for treatment of hypotensive and orthostatic circulatory disorders, e.g. hypotension in infectious diseases and in convalescence, and low blood pressure and pain following admin. of tricyclic antidepressants, antihypertensive agents and nitro cpds. The potency and duration of action of the combination of dihydroergotamine and heptaminol are greater than those of the individual components. Unlike etilefrine, heptaminol does not give rise to undesirable side-effects such as tachycardia.
No recruitment maneuver is performed. PEEP 0 cm H2O. Inspiratory oxygen concentration (FiO2) 100 % during recovery from anesthesia.
The present invention relates to external-application plaster for curing facial palsy, which mainly comprises the following components by weight proportion: 50 to 150g of red lead, 3 to 7 grub, 15 to 35g of herba siegesbeckiae and a proper amount of sesame oil. The manufacture method comprises: the herba siegesbeckiae is firstly dried in the sun and is crushed; the sesame oil is put into a special pan to be boiled; the grub is put into the pan; the red lead and the herba siegesbeckiae are sequentially put into the pan and are stirred; the materials are decocted for twenty to forty minutes with slow fire. A semi-finished product of the plaster decocted by the step is cooled. When cooled, the semi-finished product of the plaster is put on the slow fire again. The semi-finished product of the plaster is decocted during stirring until the semi-finished product of the plaster presents a viscous form. The decocted plaster is flatly laid on lining cloth, and the plaster as a finished product is obtained. The present invention has a use method that the plaster is externally stuck to a focus position on a face of a patient, and a course of treatment takes 15 days. An early patient can be healed once using the plaster. The present invention has the characteristics of scientific formulation, simple method, good therapeutic effects and low cost.
In the control condition, the patients will receive a sham stimulation, for which the control unit will be programmed to start stimulating for 1 minute then it will shut off. There is no risk related to the sham intervention since it consists of applying the same parameters used for the active session (low frequency: 20 Hz; current intensity: 2 mA; pulse width ranging from 25 to 170 µs) but for a shorter duration of time (1 minute instead of 1 hour).
Photon-initiated photoacoustic streaming (PIPS) with an Er: YAG laser has been introduced in root canal treatment to improve irrigation and facilitate the removal of bacteria in the root canal system. This study aimed to compare the antibacterial effectiveness of two different root canal irrigation techniques, conventional needle irrigation (CNI) and PIPS, using 1% sodium hypochlorite (NaOCl), in the treatment of teeth with apical periodontitis. Sixty patients with a total of sixty teeth affected by apical periodontitis were included in this study. The teeth underwent root canal therapy, and after mechanical instrumentation, they were randomly assigned to two groups (n = 30) based on the final irrigation protocol: CNI or PIPS with 1% NaOCl. Bacterial suspensions in the root canals were evaluated using Adenosine 5'-triphosphate (ATP) assay kit after mechanical instrumentation and after final irrigation. Then, a follow-up was conducted after 7 days. The results revealed that final irrigation significantly reduced ATP values in both the CNI and PIPS groups (P < 0.001). The ATP values after final irrigation was greater in the CNI group compared to the PIPS group (P < 0.001). After a 7-day follow-up, percussion tenderness and fistula were significantly resolved in both groups (P < 0.05). A multivariate linear regression model was used to identify the factors that influence post irrigation ATP values. The analysis demonstrated that pre-operative percussion tenderness (P = 0.006), the presence of a fistula (P < 0.001) and the method used in the final irrigation (P < 0.001) had a significant impact on the ATP value after final irrigation. These results indicate that employing PIPS with 1% NaOCl as the final irrigation protocol exhibited superior antibacterial effectiveness and has the potential to enhance clinical outcomes in the treatment of teeth afflicted with apical periodontitis.
Computer systems, methods, and devices for structured dynamic electronic forms are provided. The system includes a user device comprising a client form management application and a server comprising a server form management application. The client form management application generates and sends a request for a dynamic electronic form to the server. The server form management application stores the dynamic electronic form comprising separately stored form template data and form data; and merges and sends the form template data and the form data to the user device for rendering. The client form management application sends a request for a form filler package ("FFP") comprising rules for filling out and rendering the dynamic electronic form. The server form management application sends the FFP to the user device and the client form management application renders the dynamic electronic form using the merged form template data and form data and the FFP.
Updated drug label and related safety information is communicated to an electronic drug label attached to a drug package via a communication channel between the drug company and the electronic drug label. A communications terminal for communicating drug label and safety information includes a memory that stores drug labels and related safety information and a user interface that enables a user to update the drug labels and related safety information. A communications interface provides an interface to a communications system and transmits a new drug label and related safety information or updated drug label and safety information directed to a particular drug package to which an addressed electronic drug label is attached upon initiation of an authenticated user. A method for updating a drug label and related safety information remotely includes disposing an electronic drug label on drug packaging and transmitting an updated drug label and related safety information to the electronic drug label. The method includes receiving the updated drug label and safety information by the electronic drug label and updating a display of the electronic drug label with the updated drug label and related safety information. An electronic drug label includes a display for displaying drug-labeling and related safety information, a receiver to receive updated drug labeling and related safety information and a processor to update the display with the received updated drug labeling and related safety information.
The effects of fenofibrate on serum triglycerides were studied in two randomized, double-blind, placebo-controlled clinical trials of 147 hypertriglyceridemic patients. Patients were treated for eight weeks under protocols that differed only in that one entered patients with baseline TG levels of 500 to 1500 mg/dL, and the other TG levels of 350 to 500 mg/dL. In patients with hypertriglyceridemia and normal cholesterolemia with or without hyperchylomicronemia, treatment with fenofibrate at dosages equivalent to 135 mg once daily of fenofibric acid delayed-release capsules decreased primarily VLDL-TG and VLDL-C. Treatment of patients with elevated TG often results in an increase of LDL-C (Table 4).  
Table 4. Effects of Fenofibrate in Patients With Severe Hypertriglyceridemia